News
SRPT
116.55
-1.14%
-1.34
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Sarepta Therapeutics (SRPT) and Intuitive Surgical (ISRG)
TipRanks · 4h ago
As more rare disease therapies launch, their prices are rising
Therapies that treat rare diseases are among the most expensive treatments for patients. The most expensive medicine in the world, Lenmeldy, comes with a wholesale price of $4.25M. Cantor Fitzgerald says the prices of rare disease therapies have been increasing since 2021.
Seeking Alpha · 2d ago
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) does carry debt. The company had debt of US$1.24b at the end of December 2023. Debt can be a good tool for businesses that need capital to invest in growth. Despite its debt, the company has net cash of $438.3m. In the last year it managed to grow its revenue by 33% to $1.2b. We've identified 2 warning signs for SareptaTherapeutics.
Simply Wall St · 4d ago
Weekly Report: what happened at SRPT last week (0408-0412)?
Weekly Report · 4d ago
Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
Sarepta Therapeutics reported strong Q4/2023 performance. The company reported $365.1M in net product revenue, up 55% from the previous year. ELEVIDYS' Phase III trial failed to hit its primary endpoint, but showed significant improvements in motor function. Sarepta's growth prospects have led to an updated strategy and bullish outlook for the company.
Seeking Alpha · 04/11 06:27
Sarepta Therapeutics: A Buy Recommendation Amidst Undervaluation and Growth Potential for Elevidys
TipRanks · 04/10 06:19
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ)
Bluebird Bio, Sarepta Therapeutics and Jazz Pharmaceuticals have received a lot of coverage today. Bluebird Bio has a Hold rating from RBC Capital, while Sarepta Therapeutic has a Buy rating from Citi. The Healthcare sector has been the subject of a number of analyst reports.
TipRanks · 04/09 02:00
Sarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts
Seeking Alpha · 04/08 20:11
Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?
NASDAQ · 04/08 10:20
Weekly Report: what happened at SRPT last week (0401-0405)?
Weekly Report · 04/08 09:21
2 Biotech Stocks to Buy Hand Over Fist in April
Two biotech companies are a buy this month: Amgen and Sarepta Therapeutics. Amgen is one of the largest biotechs and boasts a vast pipeline. The company is going after the weight loss market. Sarepta Therapeutic specializes in developing treatments for rare diseases. Both companies have made important moves in the past year.
The Motley Fool · 04/06 12:45
Buy Rating on Sarepta Therapeutics Amidst Anticipated Drug Approval and Market Potential
TipRanks · 04/04 23:46
SAREPTA THERAPEUTICS INC <SRPT.O>: RBC CUTS TARGET PRICE TO $154 FROM $157
Reuters · 04/04 11:38
Solid Biosciences gets FDA rare pediatric disease status for DMD therapy
Healthcare Solid Biosciences gets FDA rare pediatric disease status for DMD therapy. SGT-003 for the treatment of Duchenne muscular dystrophy. The company expects the first patient in a Phase 1/2 study for the therapy to be dosed in Q2.
Seeking Alpha · 04/01 14:17
Weekly Report: what happened at SRPT last week (0325-0329)?
Weekly Report · 04/01 09:21
CCL, SPB, RARE, and VRSK are new additions to GS’ Long Duration Basket
GS’ Long Duration basket returned 3% year-to-date, compared to 6% for the equal-weight S&P 500 (RSP) Goldman Sachs analysts expect inflation to continue to be low and real yields to remain close to current levels. CCL, SPB, RARE, and VRSK are new additions to GS' Long Duration Basket.
Seeking Alpha · 03/28 17:46
Should iShares Morningstar Small-Cap Growth ETF (ISCG) Be on Your Investing Radar?
NASDAQ · 03/26 10:20
Weekly Report: what happened at SRPT last week (0318-0322)?
Weekly Report · 03/25 09:22
We Might See A Profit From Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Soon
Sarepta Therapeutics, Inc. Focuses on the discovery and development of RNA-targeted therapeutics for the treatment of rare diseases. The company posted a loss of US$536m in its most recent financial year. Consensus from 19 of the American Biotechs analysts is that the company is on the verge of breakeven. Analysts expect the company to grow 42% year-on-year. SareptaTherapeutics is expected to be profitable by 2024.
Simply Wall St · 03/23 13:04
Oppenheimer Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)
TipRanks · 03/22 11:56
More
Webull provides a variety of real-time SRPT stock news. You can receive the latest news about Sarepta Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.